From deep infiltrating endometriosis to endometriosis-associated cancer: current aspects of differential diagnosis
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2026.763
Abstract
Deep infiltrating endometriosis (DIE) is a socially significant condition that markedly reduces patients’ quality of life due to chronic pain syndrome and a high risk of infertility. In recent years, increasing evidence has emerged regarding the malignant transformation of the disease, with the malignant foci developing predominantly in the ovaries, as well as in extra-ovarian locations. The similarity of clinical manifestations, morphological characteristics, and molecular alterations between benign and malignant disease forms markedly complicates differential diagnosis. This article summarizes current concepts regarding the criteria for distinguishing deep infiltrating endometriosis from endometriosis-associated cancer. It highlights the limited evidence base and the need to develop standardized integrative approaches to improve diagnostic accuracy and stratification of oncological risk in this group of patients.
About the Authors
A. G. Solopova
Sechenov University
Russian Federation
Russian Federation
Antonina G. Solopova, MD, Dr Sci Med, Prof.
Scopus Author ID: 6505479504.
WoS ResearcherID: Q-1385-2015.
8 bldg. 2, Trubetskaya Str., Moscow 119048
A. Yu. Shatilina
Sechenov University
Russian Federation
Russian Federation
Anastasia Yu. Shatilina
8 bldg. 2, Trubetskaya Str., Moscow 119048
N. A. Martirosyan
Sechenov University
Russian Federation
Russian Federation
Naira A. Martirosyan
8 bldg. 2, Trubetskaya Str., Moscow 119048
M. R. Khadanovich
Sechenov University
Russian Federation
Russian Federation
Margarita R. Khadanovich
8 bldg. 2, Trubetskaya Str., Moscow 119048
K. N. Grigoreva
Sechenov University
Russian Federation
Russian Federation
Kristina N. Grigoreva, MD, PhD
8 bldg. 2, Trubetskaya Str., Moscow 119048
References
1. Steinbuch S.C., Lüß A.-M., Eltrop S. et al. Endometriosis-associated ovarian cancer: from molecular pathologies to clinical relevance. Int J Mol Sci. 2024;25(8):4306. https://doi.org/10.3390/ijms250843062.
2. Suda K., Cruz Diaz L.A., Yoshihara K. et al. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci. 2020;111(8):3000–9. https://doi.org/10.1111/cas.14507.
3. Kawahara N., Miyake R., Yamanaka S., Kobayashi H. A novel predictive tool for discriminating endometriosis associated ovarian cancer from ovarian endometrioma: the R2 predictive index. Cancers. 2021;13(15):3829. https://doi.org/10.3390/cancers13153829.
4. Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Research. 2019;8:F1000 Faculty Rev-529. https://doi.org/10.12688/f1000research.14817.1.
5. International working group of AAGL, ESGE, ESHRE and WES, Vermeulen N., Abrao M.S., Einarsson J.I. et al. Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification. Human Reprod Open. 2021;2021(4):hoab025. https://doi.org/10.1093/hropen/hoab025.
6. D'Alterio M.N., D'Ancona G., Raslan M. et al. Management challenges of deep infiltrating endometriosis. Int J Fertil Steril. 2021;15(2):88–94. https://doi.org/10.22074/IJFS.2020.134689.
7. Abike F., Tanoglu F.B., Sidar G. Deep pelvic endometriosis: clinical features, diagnosis, and treatment – a comprehensive review. Arch Gynecol Obstet. 2025;312(6):1857–69. https://doi.org/10.1007/s00404-025-08187-0.
8. Freytag D., Peters G., Mettler L. et al. Perioperative considerations in the treatment of endometriosis. J Turk Ger Gynecol Assoc. 2021;22(4):319–25. https://doi.org/10.4274/jtgga.galenos.2021.2021.0017.
9. Guerriero S., Condous G., van den Bosch T. et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet Gynecol. 2016;48(3):318–32. https://doi.org/10.1002/uog.15955.
10. Alkatout İ., Meinhold-Heerlein I., Keckstein J., Mettler L. Endometriosis: a concise practical guide to current diagnosis and treatment. J Turk Ger Gynecol Assoc. 2018;19(3):173–5. https://doi.org/10.4274/jtgga.2018.0026.
11. Li B., Wang Y., Wang Y. et al. Deep infiltrating endometriosis malignant invasion of cervical wall and rectal wall with Lynch syndrome: a rare case report and review of literature. Front Oncol. 2022;12:832228. https://doi.org/10.3389/fonc.2022.832228.
12. Shi S., Huang C., Tang X. et al. Identification and verification of diagnostic biomarkers for deep infiltrating endometriosis based on machine learning algorithms. J Biol Eng. 2024;18(1):70. https://doi.org/10.1186/s13036-024-00466-9.
13. Luna Russo M.A., Chalif J.N., Falcone T. Clinical management of endometriosis. Minerva Ginecol. 2020;72(2):106–18. https://doi.org/10.23736/S0026-4784.20.04544-X.
14. Machairiotis N., Vasilakaki S., Kouroutou P. Natural products: potential lead compounds for the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2020;245:7–12. https://doi.org/10.1016/j.ejogrb.2019.11.019.
15. Melki E. Endometriosis treatment with shock waves: A novel approach. Med Hypotheses. 2019;124:114–7. https://doi.org/10.1016/j.mehy.2019.02.022.
16. Mikocka-Walus A., Druitt M., O'Shea M. et al. Yoga, cognitive-behavioural therapy versus education to improve quality of life and reduce healthcare costs in people with endometriosis: a randomised controlled trial. BMJ Open. 2021;11(8):e046603. https://doi.org/10.1136/bmjopen-2020-046603.
17. Gonçalves A.V., Barros N.F., Bahamondes L. The practice of hatha yoga for the treatment of pain associated with endometriosis. J Altern Complement Med. 2017;23(1):45–52. https://doi.org/10.1089/acm.2015.0343.
18. Kajiyama H., Suzuki S., Yoshihara M. et al. Endometriosis and cancer. Free Radic Biol Med. 2019;133:186–92. https://doi.org/10.1016/j.freeradbiomed.2018.12.015.
19. Begovich E., Solopova A.G., Bitsadze V.O. et al. Endometriosis-associated cancer: modern aspects of etiopathogenesis, treatment and rehabilitation. [Aktual'nye voprosy etiopatogeneza, lecheniya i reabilitacii endometrioz-associirovannogo raka]. Obstetrics, Gynecology and Reproduction. 2021;15(3):287–94. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.206.
20. Barnard M.E., Farland L.V., Yan B. et al. Endometriosis typology and ovarian cancer risk. JAMA. 2024;332(6):482–9. https://doi.org/10.1001/jama.2024.9210.
21. Koppolu A., Maksym R.B., Paskal W. et al. Epithelial cells of deep infiltrating endometriosis harbor mutations in cancer driver genes. Cells. 2021;10(4):749. https://doi.org/10.3390/cells10040749.
22. Kvaskoff M., Mahamat-Saleh Y., Farland L.V. et al. Endometriosis and cancer: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(2):393–420. https://doi.org/10.1093/humupd/dmaa045.
23. Dawson A., Fernandez M.L., Anglesio M. et al. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience. 2018;12:803. https://doi.org/10.3332/ecancer.2018.803.
24. Mafra F., Mazzotti D., Pellegrino R. et al. Copy number variation analysis reveals additional variants contributing to endometriosis development. J Assist Reprod Genet. 2017;34(1):117–24. https://doi.org/10.1007/s10815-016-0822-1.
25. Anglesio M.S., Papadopoulos N., Ayhan А. et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376(19):1835–48. https://doi.org/10.1056/NEJMoa1614814.
26. Kordowitzki P., Mechsner S., Sehouli J. ARID1a gene as a potential early marker to tackle endometriosis-associated ovarian cancer. Aging Dis. 2023;15(6):2331–3. https://doi.org/10.14336/AD.2023.1109.
27. Ioannidou A., Sakellariou M., Sarli V. et al. New evidence about malignant transformation of endometriosis – a systematic review. J Clinical Med. 2025;14(9):2975. https://doi.org/10.3390/jcm14092975.
28. Bartiromo L., Schimberni M., Villanacci R. et al. A systematic review of atypical endometriosis-associated biomarkers. Int J Mol Sci. 2022;23(8):4425. https://doi.org/10.3390/ijms23084425.
29. Guidozzi F. Endometriosis-associated cancer. Climacteric. 2021;24(6):587–92. https://doi.org/10.1080/13697137.2021.1948994.
30. Tang L., Bian C. Research progress in endometriosis-associated ovarian cancer. Front Oncol. 2024;14:1381244. https://doi.org/10.3389/fonc.2024.1381244.
31. Katsumata N., Yasuda M., Isonishi S. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–6. https://doi.org/10.1016/S1470-2045(13)70363-2.
32. Clamp A.R., James E.C., McNeish I.A. et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol.. 2022;23(7):919–30. https://doi.org/10.1016/S1470-2045(22)00283-2.
33. Harter P., Sehouli J., Lorusso D. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–32. https://doi.org/10.1056/NEJMoa1808424.
34. Villarejo Campos P., Sánchez García S., Amo-Salas M. et al. Paclitaxel as HIPEC-drug after surgical cytoreduction for ovarian peritoneal metastases: a Randomized Phase III Clinical Trial (HIPECOVA). Curr Oncol. 2024;31(2):660–71. https://doi.org/10.3390/curroncol31020048.
35. Adilbayeva A., Kunz J. Pathogenesis of endometriosis and endometriosis-associated cancers. Int J Mol Sci. 2024;25(14):7624. https://doi.org/10.3390/ijms25147624.
36. Liu J., Ma Y., Jiang W., Xie P. Research progress on correlative prediction factors and prediction models of endometriosis associated ovarian carcinoma. Medicine. 2024;103(42):e40131. https://doi.org/10.1097/MD.0000000000040131.
37. Dochez V., Caillon H., Vaucel E. et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28. https://doi.org/10.1186/s13048-019-0503-7.
38. Tavares V., Marques I.S., Melo I.G. et al. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci. 2024;25(3):1845. https://doi.org/10.3390/ijms25031845.
39. Bi Q., Wang Y., Deng Y. et al. Different multiparametric MRI-based radiomics models for differentiating stage IA endometrial cancer from benign endometrial lesions: a multicenter study. Front Oncol. 2022;12:939930. https://doi.org/10.3389/fonc.2022.939930.
40. Tanase Y., Kawaguchi R., Takahama J., Kobayashi H. Factors that differentiate between endometriosis-associated ovarian cancer and benign ovarian endometriosis with mural nodules. Magn Reson Med Sci. 2018;17(3):231–7. https://doi.org/10.2463/mrms.mp.2016-0149.
41. Wu L.M., Li J.K. Malignant transformation of deep infiltrating endometriosis with invasion of the rectum in a 34-year-old woman. Asian J Surg. 2023;46(7):2999–3000. https://doi.org/10.1016/j.asjsur.2023.02.024.
42. Bayrak R., Yenidünya S., Haltas H. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract. 2011;207(3):156–60. https://doi.org/10.1016/j.prp.2010.12.005.
Review
For citations:
Solopova A.G., Shatilina A.Yu., Martirosyan N.A., Khadanovich M.R., Grigoreva K.N. From deep infiltrating endometriosis to endometriosis-associated cancer: current aspects of differential diagnosis. Obstetrics, Gynecology and Reproduction. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2026.763
Views:
148
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 